Printer Friendly
The Free Library
14,505,981 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

GeneLink, Inc., Files 10-KSB and Reports Revenue.


Business Editors/Health/Medical Writers

MARGATE, N.J.--(BUSINESS WIRE)--March 30, 2004

GeneLink, Inc. (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:GNLK), a biosciences company and leading provider of DNA tests created to facilitate "genetically guided" health, beauty and wellness products, filed its 10-KSB with the SEC which reports a revenue of $128,205 for its fiscal year ended December 31, 2003, a 200% increase in revenue from its fiscal year ended December 31, 2002.

"Even though the revenue is modest, we believe that this is just the beginning; it is the tip of the iceburg of things to come. GeneLink's time is now. We are positioned to break out into the personal care and anti-aging industries leading the way with Dermagenetics(TM) and GeneLink Nutragenetic Profile(TM) - a very exciting place to be," says John DePhillipo, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of GeneLink.

GeneLink's form 10-KSB for the year end 2003 can be viewed at www.sec.gov.

Forward-Looking Statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
: This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995, which provides a new "safe harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
" for these types of statements.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 30, 2004
Words:182
Previous Article:Trans Max Technologies, Inc. Announces Letter of Intent for $2,000,000 from a Major Motorcycle Aftermarket Vendor.
Next Article:Demand for Max-Viz Enhanced Vision Systems Equipment Expands -- Certification for Falcon F-900 Series Breaks More Ground.



Related Articles
GeneLink Profiled and Recommended by Dirigo Research.
GeneLink Announces the Filing of A U.S. Patent Application for a Snps Based Method to Assess Cardiovascular Risks.
GeneLink, Inc. Reports Revenue for Third Quarter 2002.
``Recurring Revenue Begins for GeneLink'': A Web Radio Series Featuring Interviews With CEOs, by IPOdesktop.com.
GeneLink Gets Strong Buy from Larry Oakley.
GeneLink Engages First Equity Capital Securities, Inc. to Provide Investment Banking Services.
Dirigo Research Recommends GeneLink, Inc.
GeneLink Signs Settlement Agreement with LAB 21.
Clinical Test Results Shows GeneLink's Dermagenetics Skin-Care Formula Reverses Signs of Aging.
GeneLink Receives International Patent for Age-Associated Oxidative Stress Test.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles